SRPT icon

Sarepta Therapeutics
SRPT

Overview Fund Activity
17.05 USD
-1.05
5.8%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
17.30
+0.25
1.47%
1 day
-5.8%
5 days
-0.87%
1 month
-18.77%
3 months
-20.92%
6 months
-83.18%
Year to date
-86.26%
1 year
-86.43%
5 years
-88.16%
10 years
-57.31%
 

About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Employees: 1,372

Healthcare Biotechnology
0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 22 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

85% more repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 86

65% more call options, than puts

Call options by funds: $132M | Put options by funds: $79.5M

4.11% less ownership

Funds ownership: 88.33% [Q1] → 84.22% (-4.11%) [Q2]

16% less funds holding

Funds holding: 426 [Q1] → 357 (-69) [Q2]

50% less first-time investments, than exits

New positions opened: 64 | Existing positions closed: 128

74% less capital invested

Capital invested by funds: $5.49B [Q1] → $1.42B (-$4.08B) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 0 (-5) [Q2]

See Fund Rankings

Research analyst outlook

22 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
71% downside
Avg. target
$21
24% upside
High target
$50
193% upside

22 analyst ratings

5  positive
23%
12  neutral
55%
5  negative
23%
Guggenheim
Debjit Chattopadhyay
$22
Buy
Reiterated
15 Sep 2025
Leerink Partners
Joseph Schwartz
$15
Market Perform
Maintained
9 Sep 2025
HC Wainwright & Co.
Mitchell S. Kapoor
$5
Sell
Reiterated
25 Aug 2025
B of A Securities
Tazeen Ahmad
$16
Underperform
Maintained
21 Aug 2025
Deutsche Bank
David Hoang
$12
Sell
Maintained
15 Aug 2025
See Analyst Rankings

Financial journalist opinion

Based on 45 articles about SRPT published over the past 30 days

Negative
The Motley Fool
12 days ago
2 Beaten-Down Stocks to Avoid Right Now
Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.
2 Beaten-Down Stocks to Avoid Right Now
Neutral
Business Wire
12 days ago
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its eighth year, the program was created to recognize individuals living with Duchenne muscular dystro.
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
Neutral
GlobeNewsWire
19 days ago
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases.
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
Negative
Seeking Alpha
20 days ago
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pick-and-shovel' suppliers like Repligen, Illumina, and Twist Biosciences, which offer more stable financial prospects.
mRNA Biotechs - Long-Term Value Risks Abound
Neutral
GlobeNewsWire
23 days ago
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Neutral
GlobeNewsWire
23 days ago
SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
Neutral
Business Wire
23 days ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
NEW YORK--(BUSINESS WIRE)---- $SRPT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Neutral
GlobeNewsWire
23 days ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Neutral
PRNewsWire
23 days ago
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm
Neutral
PRNewsWire
23 days ago
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
See News Rankings
Charts implemented using Lightweight Charts™